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Previous studies demonstrated that peroxisome-proliferator-activated receptor (PPAR)-a or PPAR-d activation
stimulates keratinocyte differentiation, is anti-inﬂammatory, and improves barrier homeostasis. Here we demon-
strate that treatment of cultured human keratinocytes with ciglitazone, a PPAR-c activator, increases involucrin and
transglutaminase 1 mRNA levels. Moreover, topical treatment of hairless mice with ciglitazone or troglitazone
increases loricrin, involucrin, and ﬁlaggrin expression without altering epidermal morphology. These results in-
dicate that PPAR-c activation stimulates keratinocyte differentiation. Additionally, PPAR-c activators accelerated
barrier recovery following acute disruption by either tape stripping or acetone treatment, indicating an improve-
ment in permeability barrier homeostasis. Treatment with PPAR-c activators also reduced the cutaneous inﬂam-
matory response that is induced by phorbol 12-myristate-13-acetate, a model of irritant contact dermatitis and
oxazolone, a model of allergic contact dermatitis. To determine whether the effects of PPAR-c activators are
mediated by PPAR-c, we next examined animals deﬁcient in PPAR-c. Mice with a deﬁciency of PPAR-c specifically
localized to the epidermis did not display any cutaneous abnormalites on inspection, but on light microscopy there
was a modest increase in epidermal thickness associated with an increase in proliferating cell nuclear antigen
(PCNA) staining. Key functions of the skin including permeability barrier homeostasis, stratum corneum surface
pH, and water-holding capacity, and response to inﬂammatory stimuli were not altered in PPAR-c-deﬁcient ep-
idermis. Although PPAR-c activators stimulated loricrin and ﬁlaggrin expression in wild-type animals, however, in
PPAR-c-deﬁcient mice no effect was observed indicating that the stimulation of differentiation by PPAR-c activators
is mediated by PPAR-c. In contrast, PPAR-c activators inhibited inﬂammation in both PPAR-c-deﬁcient and wild-
type mouse skin, indicating that the inhibition of cutaneous inﬂammation by these PPAR-c activators does not
require PPAR-c in keratinocytes. These observations suggest that thiazolidindiones and perhaps other PPAR-c
activators maybe useful in the treatment of cutaneous disorders.
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Three peroxisome-proliferator activated receptors (PPAR)
have been identified: a (NR1C1), d (also known as b)
(NR1C2), and g (NR1C3). PPAR-a is predominately ex-
pressed brown adipose tissue and liver, and is also present
in the kidney, heart, skeletal muscle, and the epidermis
(Desvergene and Wahli, 1999; Kliewer et al, 2001). PPAR-a
is an important regulator of lipid catabolism, mediating fatty
acid oxidation, fatty acid uptake, and lipoprotein assembly
and transport (Schoonjans et al, 1996; Desvergene and
Wahli, 1999; Kliewer et al, 2001). PPAR-d is ubiquitously
expressed, including in the epidermis, and is predominately
found in the intestine, kidney, and heart (Desvergene and
Wahli, 1999; Kliewer et al, 2001). It is expressed at higher
levels during embryogenesis, and studies suggest that
PPAR-d may participate in embryo implantation and dec-
idualization (Basu-Modak et al, 1999; Kliewer et al, 1999;
Lim et al, 1999; Michalik et al, 2001). Very recent studies
have indicated a role for PPAR-d in regulating fatty acid
oxidation (Wang et al, 2003). PPAR-g is most highly ex-
pressed in adipose tissue, and to a lesser extent in the
colon, adrenal glands, spleen, and epidermis, where it
mediates storage of fatty acids and regulates lipogenic
pathways (Brun et al, 1997; Kliewer et al, 2001).
Although the PPAR classically are seen as regulators
of lipid metabolism, activation of the PPAR produces
additional and varied effects on the epidermis. PPAR-a
stimulates differentiation and apoptosis and decreases
proliferation both in cultured human keratinocytes and1These authors contributed equally to this study.
Abbreviations: KGM, keratinocyte growth medium; PCNA, prolif-
erating cell nuclear antigen; PPAR, peroxisome-proliferator-acti-
vated receptor; TEWL, transepidermal water loss; TPA, phorbol 12-
myristate-13-acetate; TUNEL, Tdt-mediated dUTP nick end labeling
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in vivo when applied topically to mouse skin (Hanley et al,
1997, 1998; Komuves et al, 2000a). The pro-differentiating,
anti-proliferative effects of PPAR-a activators also occur in
animal models of epidermal hyperproliferation (Komuves
et al, 2000b). Moreover, topical treatment with PPAR-a ac-
tivators accelerates permeability barrier recovery following
acute barrier disruption (Komuves et al, 2000a). Lastly,
treatment with PPAR-a activators inhibits cutaneous inflam-
mation in animal models of irritant contact dermatitis
(phorbol 12-myristate-13-acetate (TPA) treatment) and al-
lergic contact dermatitis (oxazalone treatment) (Sheu et al,
2002). With regard to PPAR-d, we have recently shown that
activation with GW 1514, a highly specific PPAR-d activator,
stimulates differentiation both in vitro in cultured human
keratinocytes and in vivo when applied topically to normal
and hyperproliferative mouse skin (Schmuth et al, 2004).
Other investigators have also shown that PPAR-d activators
stimulate differentiation in cultured keratinocytes (Wester-
gaard et al, 2001). Additionally, over-expression of PPAR-d
induced differentiation in cultured keratinocytes and pro-
tected against cell death in vitro (Tan et al, 2001; Di-Poi et al,
2002). In contrast to PPAR-a activators, however, PPAR-d
activators neither inhibit keratinocyte proliferation nor stim-
ulate apoptosis (Schmuth et al, 2004). Similar to PPAR-a,
PPAR-d activators stimulate permeability barrier home-
ostasis and inhibit TPA-induced cutaneous inflammation
(Schmuth et al, 2004). Moreover, PPAR-d-deficient mice
display an increased susceptibility to phorbol ester-induced
epidermal hyperplasia, suggesting that PPAR-d plays an
important role in vivo in modulating proliferation (Peters et al,
2000). Lastly, Michalik et al (2001) observed a delay in
wound healing in heterozygote PPAR-d-deficient mice.
PPAR-g is expressed in the epidermis and its expression
increases with differentiation (Rivier et al, 1998). The role of
PPAR-g in the epidermis is not well understood. In normal
human and psoriatic cultured keratinocytes, PPAR-g acti-
vators are anti-proliferative (Ellis et al, 2000). Moreover, in
a psoriatic mouse model, PPAR-g activators reduce epider-
mal hyperplasia (Ellis et al, 2000). Additionally, in one clinical
study, patients with chronic, stable plaque psoriasis dem-
onstrated improvement after oral therapy with the PPAR-g
agonist, troglitazone (Ellis et al, 2000). Another study, how-
ever, did not demonstrate a beneficial effect of topical
treatment with PPAR-g activators in patients with psoriasis
(Kuenzli and Saurat, 2003). The purpose of this study was to
further characterize the role of PPAR-g in the epidermis.
Results
Topical treatment with PPAR-c activators stimulates dif-
ferentiation Repeated topical application twice per day for
4 d with PPAR-g agonists resulted in no consistent change
in epidermal histology and epidermal thickness was similar
in treated and control mice (data not shown). The PPAR-g
activators, however, slightly increased keratinocyte prolifer-
ation, as measured by the PCNA method (supplemental
Fig S1a: ciglitazone: 16.32  0.31 cells per inch, po0.001;
troglitazone: 15.87  0.22 cells per inch, po0.01; vehicle:
14.81  0.21 cells per inch). This increase in proliferation
was balanced by an increase in apoptosis, measured by the
Tdt-mediated dUTP nick end labeling (TUNEL) assay (sup-
plemental Fig S1b). We next determined whether topical
treatment with PPAR-g activators induce epidermal differ-
entiation. Topical treatment with ciglitazone or troglitazone
(10 mM), twice a day for 4 d, resulted in an increase in
immunostaining of the differentiation markers, involucrin
and loricrin in comparison to controls treated with vehicle
alone (supplemental Fig S2a). Additionally, using in situ hy-
bridization, an increase in filaggrin mRNA was observed
with PPAR-g treatment (supplemental Fig S2b). These re-
sults demonstrate that topical application of PPAR-g acti-
vators to mouse skin stimulates epidermal proliferation,
differentiation, and apoptosis with no net change in epider-
mal morphology.
Effect of PPAR-c activators on cultured human keratin-
ocytes To further demonstrate the role of PPAR-g activa-
tion in stimulating keratinocyte differentiation we next
determined the effects of ciglitazone in vitro on cultured
human keratinocytes. As shown in Fig 1, ciglitazone treat-
ment increased mRNA levels of both involucrin and trans-
glutaminase 1 in keratinocytes grown in either low or high
calcium. Of note is that the increase in both involucrin and
transglutaminase 1 mRNA levels induced by ciglitazone
treatment was greater than that observed with high calcium,
the standard method for stimulating keratinocyte differen-
tiation. These results confirm the in vivo studies in mice and
demonstrate that a PPAR-g activator stimulates human
keratinocyte differentiation.
PPAR-c activators improve permeability barrier home-
ostasis Because epidermal permeability barrier function is
in part dependent on keratinocyte differentiation, we next
examined the effect of PPAR-g activators on barrier home-
ostasis. Following pre-treatment (twice a day for 4 d) with
either ciglitazone or troglitazone, we observed that barrier
recovery was increased at 6 h following disruption of the
barrier by either tape stripping or acetone treatment (Fig 2).
Thus, topical treatment with PPAR-g activators improves
permeability barrier homeostasis, the final product of epi-
dermal differentiation.
PPAR-c activators suppress cutaneous inﬂamma-
tion We next assessed the anti-inflammatory activity of
PPAR-g agonists. Employing the TPA model of irritant con-
tact dermatitis, treatment with ciglitazone or troglitazone re-
duced the magnitude of the TPA-induced increase in both
ear thickness and ear weight (ciglitazone: 46% and 44%;
troglitazone: 69% and 68%, respectively, for ear thickness
and weight (Fig 3). Remarkably, at these doses, ciglitazone
and troglitazone displayed an anti-inflammatory effect com-
parable to that observed with the potent glucocorticoid, clo-
betasol. We next examined hematoxylin–eosin (H&E)-stained
sections of the ears from the TPA-treated animals. As seen in
supplemental Fig S3, vehicle treatment alone following TPA-
induced inflammation resulted in a marked increase in ear
thickness and an inflammatory infiltrate. Treatment with cig-
litazone or troglitazone decreased ear thickness and the
number of inflammatory cells compared to vehicle treatment
alone. These results demonstrate that PPAR-g activators are
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effective in inhibiting cutaneous inflammation in a TPA-in-
duced irritant contact dermatitis model.
We next examined the effects of the PPAR-g agonists in
the oxazolone model of allergic contact dermatitis. As seen
in Fig 4, ear thickness and ear weight increased (1.31-fold)
following topical oxazolone application to sensitized ani-
mals (vehicle controls), whereas topical treatment with ei-
ther troglitazone or ciglitazone significantly reduced the
oxazolone-induced inflammation, as shown by both de-
creased ear thickness (Fig 4) (31% and 27%, respectively,
for troglitazone and ciglitazone) and decreased ear weight
(Fig 4) (39% and 27%, respectively, for troglitazone and
ciglitazone). Treatment with the potent glucocorticoid, clo-
betasol, produced a greater anti-inflammatory effect (78%
reduction in ear thickness and weight, respectively) than did
the PPAR-g agonists at the concentrations used in this
study. Moreover, H&E-stained sections demonstrated an
increase in ear thickness and inflammatory cells in the ox-
azolone-treated animals treated with vehicle alone, whereas
topical treatment with either ciglitazone or troglitazone
Figure 1
Effect of PPAR gamma activators on involucrin and transglutami-
nase 1 mRNA levels. Second-passage keratinocytes isolated from
human newborn foreskins were cultured in serum-free keratinocyte
growth medium Cells were treated with 5 mM ciglitazone at pre-con-
fluence (60%–70%) in either low (0.3 mM) or high (1.2 mM) calcium
conditions. Control keratinocytes were treated with vehicle (0.05% et-
hanol). Cells were harvested after 24 h. Involucrin and transglutaminase
1 mRNA levels were measured by northern blotting as described in the
Materials and Methods section. (A). Northern blot probed with in-
volucrin. (B). Quantitation of involucrin northern blot. (C). Northern blot
probed with transglutaminase I. (D). Quantitation of northern blot
probed with transglutaminase I. N¼4 for the groups.
Figure2
Effect of topical PPAR-c activators on permeability barrier repair.
Hairless mice were treated with vehicle or ciglitazone twice daily for 4 d.
Subsequently, the animals were treated by either repeated application
of cellophane tape stripping (A) or repeated acetone application (B)
until the TEWL reached 6–8 mg per cm2 per h. TEWL was measured at
3 and 6 h after barrier disruption. Recovery of barrier function is ex-
pressed as a percentage of time zero and data are presented as
meanþSEM; N number and significance are shown in the figures.
Figure3
Effect of PPAR-c activators on cutaneous inflammation as as-
sessed by ear weight and ear thickness in TPA-induced irritant
model. Both inner and outer surface of both ears were topically treated
with 10 mL of 0.03% phorbol 12-myristate-13-acetate (TPA). Forty-five
minutes and 4 h after TPA application, 20 mL of test compounds were
topically applied to both inner and outer surface of the left ear, and the
right ear was treated with acetone alone. The ear thickness was meas-
ured at 18 h following TPA application. The results are expressed as
percentage increase in ear thickness (A, C) or in ear weight (B, D)
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reduced both the ear thickness and the amount of inflam-
matory infiltrate compared to the vehicle-treated animals
(supplemental Fig S4). Thus, activators of PPAR-g reduce
inflammation in a cutaneous model of allergic contact
dermatitis.
PPAR-c deﬁciency minimally alters cutaneous structure
and function The gross cutaneous appearance of mice
deficient in PPAR-g in the epidermis was normal except for
patchy hair loss in older animals (in young animals,o16 wk
of age no abnormalities were observed). Next, we examined
the skin by light microscopy. H&E-stained sections revealed
a modest increase in epidermal thickness in the PPAR-g-
deficient mice (supplemental Fig S5a) (0.636  0.0113 vs.
0.529  0.0225 mm; po0.05; n¼5). In concordance with
the increase in epidermal thickness, PCNA staining was in-
creased in the PPAR-g-deficient mice, indicating increased
keratinocyte proliferation (supplemental Fig S5b). Apopto-
sis, however, as measured by the TUNEL assay, was un-
changed in the PPAR-g-deficient mice (data not shown).
Similarly, the expression of differentiation markers was also
not altered in PPAR-g-deficient mice (supplemental Fig S6).
We next examined several key functions of the epidermis. In
PPAR-g-deficient mice, stratum corneum pH, basal trans-
epidermal water loss (TEWL), and stratum corneum water-
holding capacity were all similar to wild-type mice (data not
shown). Additionally, permeability barrier recovery following
acute disruption by tape stripping was normal in PPAR-g-
deficient skin, as was the cutaneous inflammatory response
to TPA treatment (control 103%  10.5% and PPAR-g
knockout (KO) 81%  8.6% increase in ear thickness).
Lastly, electron microscopy revealed that the number and
appearance of lamellar bodies and the lamellar secretory
system were similar in PPAR-g and wild-type mice (data not
shown). Thus, except for slight epidermal hyperplasia and
patchy hair loss with aging, the structure and function of
PPAR-g-deficient murine skin appears normal.
The role of PPAR-c in mediating the effects of PPAR-c
activators We next utilized these PPAR-g-deficient mice
to determine the specificity of the effects of the PPAR-g ac-
tivators on the epidermis. As shown in supplemental Fig S6,
loricrin and filaggrin staining were similar in PPAR-g-defi-
cient and wild-type mice. In the wild-type mice, topical cig-
litazone treatment again increased the staining for both
loricrin and filaggrin (supplemental Fig S6). In contrast, in
PPAR-g-deficient epidermis, topical treatment with ciglita-
zone did not increase either loricrin or filaggrin-staining,
indicating that the stimulation of differentiation induced by
PPAR-g activators requires PPAR-g. Finally, we determined
the effect of PPAR-g activators on inflammation in the
PPAR-g-deficient mice. As shown in Fig 5, ciglitazone in-
hibited inflammation in the PPAR-g-deficient and wild-type
skin to a similar degree (control 30% and PPAR-g KO 31%),
indicating that the inhibition of cutaneous inflammation by
these PPAR-g activators does not require PPAR-g expres-
sion in keratinocytes.
Discussion
This study demonstrates that activators of PPAR-g stimu-
late epidermal differentiation both in vitro, using cultured
human keratinocytes, and in vivo, when applied topically
to mouse skin. That this stimulation of differentiation is
Figure 4
Effect of PPAR-c activators on cutaneous inflammation as as-
sessed by ear weight and ear thickness in oxazolone-induced al-
lergic model. Both inner and outer surface of both ears were topically
treated with 10 mL of 2% (wt/vol in acetone) oxazolone (4-ethoxymeth-
ylene-2-phenyl-2-oxazolin-5-one) 1 wk following primary sensitization
with 20 mL of 15% oxazolone. Forty-five minutes and 4 h after appli-
cation of 2% oxazolone, 10 mL of test compounds was topically applied
to both inner and outer surface of the left ear, and the right ear was
treated with acetone alone. The ear thickness was measured at 18 h
following oxazolone application. The results are expressed as percent-
age increase in ear thickness (A) or in ear weight (B)
Figure5
Effect of PPAR-c activators on cutaneous inflammation in PPAR-c-
deficient mice. Both inner and outer surface of both ears were top-
ically treated with 10 mL of 0.03% phorbol 12-myristate-13-acetate
(TPA). Forty-five minutes and 4 h after TPA application, 20 mL of test
compounds were topically applied to both inner and outer surface of
the left ear, and the right ear was treated with acetone alone. The ear
thickness was measured at 18 h following TPA application. The result
was expressed as percentage increase (mean  SEM, n¼20)
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mediated by PPAR-g is shown by the absence of an effect in
mice lacking PPAR-g in the epidermis. The stimulation of
epidermal/keratinocyte differentiation by PPAR-g activators
is very similar to previous observations by this laboratory
using activators of PPAR-a, PPAR-d, and LXR (Hanley et al,
1998, 2000; Komuves et al, 2000a, 2002; Schmuth et al,
2004). Lipid compounds activate PPAR (fatty acids) and
LXR (oxidized cholesterol) and hence these nuclear hor-
mone receptors are liposensors that are capable of mon-
itoring intracellular lipid levels and then regulating the
expression of a variety of different genes (Chawla et al,
2001b). During epidermal differentiation, abundant fatty acids
and cholesterol are required for the formation of lamellar
bodies in stratum granulosum cells (Proksch et al, 1993).
Prior to terminal differentiation, these lamellar bodies are
secreted into the extracellular spaces of the stratum corn-
eum, where they form the lamellar membranes that mediate
the barrier to the movement of water and solutes (Elias and
Feingold, 2001). In parallel with the formation of lamellar
bodies and lamellar membranes, keratinocytes differentiate
into corneocytes which are encased by a cornified envelope
consisting of loricrin, involucrin, and other structural pro-
teins that are extensively cross-linked by transglutaminases
(Fuchs, 1990; Eckert et al, 1997; Elias and Feingold, 2001).
The cornified envelope provides the rigidity and mechanical
strength to the stratum corneum. Although the formation of
the extracellular lipid component of the stratum corneum
and the corneocytes are usually considered as separate
independent processes that occur simultaneously during
keratinocyte differentiation, it is possible that these proces-
ses are coordinately regulated. The increase in lipids in
stratum granulosum cells could activate PPAR and/or LXR,
thereby stimulating the expression of filaggrin, loricrin, in-
volucrin, transglutaminase 1, and perhaps other proteins
required for corneocyte formation (Fig 6). Such cross-talk
regulation would be advantageous to allow for the coordi-
nate formation of both the corneocytes and extracellular
lamellar membranes that comprise the stratum corneum.
Although PPAR-a, PPAR-d, PPAR-g, and LXR activators
all stimulate keratinocyte differentiation there are differ-
ences in the effects of these receptors. Specifically, activation
of PPAR-a and LXR inhibits keratinocyte proliferation lead-
ing to a decrease in epidermal thickness (Komuves et al,
2000a, 2002). In contrast, topical treatment with activators
of PPAR-d and PPAR-g do not result in epidermal thinning
(Schmuth et al, 2004 present study). In fact, in the present
study activation of PPAR-g caused a slight increase in
PCNA staining indicating increased proliferation. Along sim-
ilar lines PPAR-a and LXR activators increased apoptosis,
whereas PPAR-d activators had no effect. In the present
study, PPAR-g activators caused a slight increase in
apoptosis. Importantly, activation of all the liposensors,
PPAR-a, PPAR-d, PPAR-g, and LXR, improves permeability
barrier homeostasis (Komuves et al 2000a, 2002; Schmuth
et al, 2004). After disruption of the barrier, the ability of the
epidermis to restore barrier function to normal is acceler-
ated in animals treated with PPAR or LXR activators. The
precise mechanism by which barrier homeostasis is im-
proved is unknown but studies by Rivier et al (2000) have
shown that PPAR-a activators stimulate the synthesis of the
lipids that are required for the formation of lamellar bodies.
It is, therefore, possible that activation of PPAR and LXR not
only stimulate formation of the cornified envelope and fi-
laggrin but also play a role in regulating the synthesis of the
lipids required for the formation of lamellar bodies.
Previous studies have shown that PPAR-a, PPAR-d, and
LXR activators inhibit cutaneous inflammation (Sheu et al,
2002; Fowler et al, 2003; Schmuth et al, 2004). In the
present study, we demonstrate that PPAR-g activators also
inhibit the inflammation induced in animal models of both
irritant and allergic contact dermatitis. The inhibition of in-
flammation, however, was not only observed in normal mice
but was also observed in mice deficient in PPAR-g in the
epidermis demonstrating that this anti-inflammatory effect
does not require PPAR-g expression in the epidermis. In
contrast, previous studies have shown that the inhibition of
inflammation by PPAR-a and LXR activators did not occur in
PPAR-a- or LXR-a/b-deficient mice, respectively, indicating
that the anti-inflammatory effects are mediated by PPAR-a
and LXR. Studies by other investigators have similarly
shown that thiazolidindione PPAR-g activators, similar to
those used in the present study, have anti-inflammatory ef-
fects on macrophages independent of PPAR-g (Chawla et al,
2001a). Thus, although the stimulation of differentiation by
PPAR-g activators is mediated by PPAR-g, the inhibition
of inflammation does not require PPAR-g expression in
the epidermis. Nevertheless, these thiazolidindione drugs,
which are widely used in the treatment of Type 2 diabetes,
maybe therapeutically useful either topically or orally in the
treatment of inflammatory skin disorders. It has been re-
ported that psoriasis is improved in diabetic patients being
treated with troglitazone (Ellis et al, 2000).
Animals that are deficient in PPAR-g die in utero (Barek
et al, 1999). Therefore, in the present study, we employed
animals that had a deficiency of PPAR-g localized to the
epidermis. Despite the absence of PPAR-g in their epider-
mis, the gross cutaneous appearance of these animals was
normal except for patchy hair loss in older animals. Sim-
ilarly, the morphological appearance using both light and
electron microscopy was normal except for a slight increase
in epidermal thickness and an increase in PCNA staining. It
may seem paradoxical that deficiency of PPAR-g and ac-
tivation of PPAR-g both lead to increased PCNA staining in
Figure 6
Role of lipids in coordinating SC formation.
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the epidermis but such paradoxical responses are often
seen with nuclear hormone receptors. For example, previ-
ous studies by our laboratory have shown that LXR defi-
ciency and LXR stimulation both reduce epidermal
thickness and PCNA staining (Komuves et al, 2002). Sim-
ilarly, LXR activation increases cholesterol 7-a hydroxylase
activity in the liver, whereas LXR deficiency also induces an
increase in the activity of this enzyme in liver (Peet et al,
1998). It has been hypothesized that the basis for these
seemingly paradoxical observations is that although acti-
vation of a nuclear hormone receptor will stimulate gene
expression, the nuclear hormone receptor alone will inhibit
gene expression. Thus, deficiency in the nuclear hormone
receptor could result in an increase in gene expression. Fi-
nally, we did not observe any functional abnormalities in the
skin of animals deficient in PPAR-g in the epidermis. Spe-
cifically, stratum corneum pH, stratum corneum water-hold-
ing capacity, basal TEWL, and the ability to recover barrier
function after acute disruption were not altered in PPAR-g-
deficient mice. These observations of a paucity of abnor-
malities in animals deficient in PPAR-g in the epidermis is
very similar to our previous observations in PPAR-a- and
LXR-a/b-deficient animals in which we also observed min-
imal cutaneous alterations (Komuves et al, 2000a, 2002). It
is likely that the effects of these receptors on the epidermis
are redundant such that the absence of any single receptor
has only minimal effects.
In summary, in the present study we demonstrate that
thiazolidindiones stimulate keratinocyte differentiation by
activating PPAR-g, and decrease cutaneous inflammation, a
response that is not dependent on PPAR-g in keratinocytes.
These observations raise the possibility that thiazolidindi-
ones and perhaps other PPAR-g activators will be useful in
the treatment of a variety of cutaneous disorders.
Materials and Methods
All animal procedures were approved by the Animal Studies Sub-
committee of the San Francisco Veterans Administration Medical
Center and were performed in accordance with their guidelines.
The Committee on Human Research at the University of Cal-
ifornia, San Francisco, California, approved studies with human
keratinocytes.
Animals—production of PPAR gamma KO mice Mice harboring
LoxP-flanked PPAR-g alleles (PPAR-gL2/L2) that will be described in
detail elsewhere, were bred with K14-Cre transgenic mice, in which
the Cre recombinase is expressed under the control of the human
keratin 14 (K14) promoter (Li et al, 2000). The resulting K14-Cre (tg/0)/
PPAR-gL2/L2 mice in which PPAR-g is selectively disrupted in ep-
idermal keratinocytes, and age- and sex-matched PPAR-gL2/L2
control littermates were analyzed.
In vivo studies In order to study the effects of the PPAR-g ac-
tivators on differentiation, normal hairless mice (males, age 6–8 wk
from Charles River, Wilmington, Massachusetts) or PPAR-g kera-
tinocyte selective KO mice and wild-type controls were treated on
one side of the shaved flank (2.5 cm2) with 40 mL of 10 mM cig-
litazone (Cayman Chemical, Ann Arbor, Michigan), 10 mM troglita-
zone (BioMol, Plymouth Meeting, Pennsylvania), or with vehicle
(propylene glycol: ethanol 7:3 ratio) twice a day for 4 d. Biopsies
were obtained and tissue samples were fixed overnight at 41C in
freshly prepared 4% formaldehyde in phosphate-buffered saline
(PBS), and embedded in paraffin for immunohistochemical anal-
ysis and in situ hybridization.
Epidermal proliferation Epidermal thickness was determined
on H&E-stained sections using a 40x objective and a computer-
generated micrometer (Carl Zeiss Vision, Munich, Germany). Epider-
mal thickness was defined as the distance between the basement
lamina and the stratum granulosum–stratum corneum interface.
For the detection of proliferating keratinocytes, paraffin sections (5
mm) were processed and stained using a biotinylated anti-prolif-
erating cell nuclear antigen (CalTag Laboratories, Burlingame, Cal-
ifornia) as described previously (Komuves et al, 2000a, 2002). The
proliferating pool of keratinocytes was determined by quantitating
PCNA positive nuclei per inch of basement membrane.
Epidermal apoptosis The TUNEL assay was performed using the
in situ cell death detection kit (Roche Molecular Diagnostics, In-
dianapolis, Indiana) according to the manufacturer’s instructions
using FITC-labeled dUTP.
Immunohistochemistry for epidermal differentiation markers
In order to assess epidermal differentiation, paraffin-embedded
sections (flank) (5 mm) were incubated overnight with affinity-pu-
rified rabbit antibodies, specific for involucrin (1:1000), filaggrin
(1:2000), and loricrin (1:1000) (Babco, Berkeley, California) as de-
scribed previously (Komuves et al, 2000a, 2002).
In situ hybridization for proﬁlaggrin Digoxigenin-labeled RNA
probes for profilaggrin (coding region, 300 bases) (Yuspa et al,
1989) were made from linearized cDNA sequences (a gift from S.
Yuspa, NIH) using reagents supplied by Boehringer-Mannheim
(Indianapolis, Indiana). In situ hybridization was performed as
described earlier (Komuves et al, 1998).
Microscopy and Imaging The paraffin sections (H&E, differenti-
ation markers, PCNA, TUNEL) were examined with a Zeiss (Axio-
plan 2) microscope (Jena, Germany) using brightfield optics. Digital
images were captured with AxioVision software 2.05 (Carl Zeiss
Vision, Munich, Germany).
Electron microscopy Skin biopsies were taken and samples
were minced too0.5 mm3, fixed in Karnovsky’s fixative overnight,
and post-fixed with either 0.5% ruthenium tetroxide or 2% aque-
ous osmium tetroxide, containing 1.5% potassium ferrocyanide,
and analyzed by electron microscopy as described previously (Hou
et al, 1991).
Assessment of epidermal function Basal cutaneous permeabil-
ity barrier function was determined by measuring TEWL with an
electronic water analyzer (MEECO, Warrington, Pennsylvania). The
kinetics of barrier recovery were then determined after acute dis-
ruption by sequential applications of cellophane tape (Shurtape,
Shurtape Technologies, Hickory, North Carolina) or acetone treat-
ment (TEWL*6–8 mg per cm2 per h) at 3 and 6 h post-disruption,
as described previously (Komuves et al, 2000a, b). Surface pH was
measured with a flat glass electrode (Mettler-Toledo, Giessen,
Germany), using a pH meter (skin pH Meter PH 900, Courage
and Khazaka, Cologne, Germany). Stratum corneum hydration was
measured with the capacitance-based Corneometer CM 825
(Courage and Khazaka), with values reported in arbitrary units.
Anti-inﬂammatory models and studies Adult CD-1 male and fe-
male mice, 6–10 wk of age, purchased from Charles River Labs
(Wilmington, Massachusetts), or PPAR-g KO mice and wild-type
controls were used in these studies. TPA (Sigma, St Louis, Mis-
souri)-induced irritant contact dermatitis was instituted by the top-
ical application of 10 mL 0.03% (wt/vol in acetone) TPA to both the
inner and outer surface (20 mL total) of both ears. Forty-five minutes
and 4 h after TPA application, 20 mL of test compounds, ciglitazone
(10 mM) (Cayman Chemical, Ann Arbor, Michigan) or troglitazone
(10 mM) (BioMol, Plymouth Meeting, Pennsylvania) were applied
to both surfaces of the left ear and the right ear was treated with
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acetone vehicle alone (40 mL total per ear). Identical treatments
were performed with 20 mL of 0.05% clobetasol (1.1 mM), a topical
anti-inflammatory glucocorticoid, which served as a positive con-
trol. All chemical compounds were dissolved in absolute acetone
(reagent grade) vehicle.
Allergic contact dermatitis was induced by sensitization (for 2 d)
on the shaved backs of CD-1 female mice with 20 mL of 15% (wt/
vol in acetone) oxazolone (4-ethoxymethylene-2-phenyl-2-ox-
azolin-5-one), followed by challenge on day 7 with a single top-
ical application of 10 mL oxazolone (2%) to the inner and outer
surfaces of both ears. This challenge was followed by treatment
with ciglitazone (10 mM), troglitazone (10 mM), clobetasol (0.05%),
or acetone at 45 min and 4 h.
Eighteen hours after the inflammatory insult induced by either
TPA or oxazolone, inflammation was assessed as the percent in-
crease in ear thickness and/or ear weight in the treated left ear
versus the vehicle-treated right ear. Ear thickness was measured
with a digital caliper (Mitutoyo, Tokyo, Japan), followed by a 6 mm-
punch biopsy to ascertain changes in ear weights.
After samples were obtained for assessment of ear thickness/
weight, biopsies were obtained from adjacent sites and fixed in
4% freshly prepared formaldehyde in PBS and stained with H&E.
Cell culture, cell proliferation, and mRNA measurements Sec-
ond-passage keratinocytes isolated from human newborn fore-
skins were cultured in serum-free keratinocyte growth medium
(KGM; Clonetics, San Diego, California). Cells were treated with
5 mM ciglitazone at pre-confluence (60%–70%) in either low (0.3 mM)
or high (1.2 mM) calcium conditions. Control keratinocytes were
treated with vehicle (0.05% ethanol). Cells were harvested after
24 h. Total RNA was isolated using TriReagent (Sigma), elect-
rophoresed, transferred to a nylon membrane (NytranN, Schlei-
cher & Schuell, Dassel, Germany) and hybridized overnight at 651C
with 32P-labeled cDNA probes for involucrin (gift from Dr Howard
Green, Harvard University) or transglutaminase 1 (a gift from Dr
Robert Rice). To control for equal loading blots were probed with
GAPDH. Bands of the reported size were quantified by densi-
tometry using QuantityOne Software (BioRad, Hercules, California).
Statistical analyses All statistical analyses were performed using
Prism 3 software (Graph Pad Software, San Diego, California).
Results were compared between multiple groups, using ANOVA,
and expressed as mean  SEM. When results between pairs were
analyzed, the Student’s t-test was used.
This study was supported by National Institutes of Health grants HD
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Supplementary Material
The following material is available from http://www.blackwellpublish-
ing.com/products/journals/suppmat/JID/JID23235/JID23235sm.htm
Figure S1
Effects of PPAR-c activators on epidermal proliferation and
apoptosis. Skin of mice was topically treated twice daily for 4 d with
vehicle (propylene glycol: ethanol, 7:3, vol/vol) or with ciglitazone or
troglitazone. Epidermal proliferation was measured by PCNA-staining
(A) and apoptosis was assessed by TUNEL staining (B).
Figure S2
Effect of topical PPAR-c activators on epidermal differentiation.
Skin of mice was topically treated twice daily for 4 d with vehicle (pro-
pylene glycol: ethanol, 7:3, vol/vol) or with the PPAR-g activators,
ciglitazone or troglitazone. Involucrin and loricrin expression were
assessed by immunohistochemistry (A). Filaggrin expression was as-
sessed by in situ hybridization (B).
Figure S3
Effect of PPAR-c activators on cutaneous morphology in the TPA
model of irritant contact dermatitis. Both inner and outer surface of
both ears were topically treated with 10 mL of 0.03% phorbol 12-my-
ristate-13-acetate (TPA). Forty-five minutes and 4 h after TPA applica-
tion, 20 mL of test compounds were topically applied to both inner and
outer surface of the left ear and the right ear was treated with acetone
alone. The ear thickness was measured at 18 h following TPA appli-
cation. Epidermal morphology was assessed by H&E staining.
Figure S4
Effect of PPAR-c activators on cutaneous morphology in the ox-
azolone model of allergic contact dermatitis. Both inner and outer
surface of both ears were topically treated with 10 mL of 2% (wt/vol in
acetone) oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) 1
wk following primary sensitization with 20 mL of 15% oxazolone. Forty-
five minutes and 4 h after application of 2% oxazolone, 10 mL of test
compounds was topically applied to both inner and outer surface of the
left ear, and the right ear was treated with acetone alone. The ear
thickness was measured at 18 h following oxazolone application. Ep-
idermal morphology was assessed by H&E staining.
Figure S5
Morphological changes in PPARc-deﬁcient mice. Mouse skin from
both wilditype and PPAR-g KO were obtained for paraffin sections.
Both H&E staining (A) and PCNA staining (B) were used to analyze the
morphological changes in PPAR-g KO and wild-type mice.
Figure S6
Effect of topical PPAR-c activators on epidermal differentiation in
PPAR-c-deﬁcient mice. Both wild-type and PPAR-g KO animals were
topically treated with 40 mL of 10 mM ciglitazone in acetone for 4 d. A
separate group of wild-type and PPAR-g KO animals were treated with
vehicle alone for 4 d and served as controls. Skin biopsy was obtained
for paraffin sections. Both filaggrin (A) and loricrin (B) staining were
used to analyze epidermal differentiation.
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